The method of treatment of cancer patients

 

(57) Abstract:

The invention relates to medicine and can be used for head and neck tumors, biliodigestive zone of the rectum. The method includes chemotherapy 5-fluorouracil followed by radiotherapy in combination with platinum source drug in the first three days of exposure. When this prescribed course of hydroxyacetone within three days prior to radiation therapy, and in the first two or three days along with radiation therapy 500 mg when the weight of the patient of 70 kg, 1000 mg weight over 70 kg, 1500 mg by weight more than 95 kg orally twice a day with a break at 12 o'clock, and platinochloride the drug is administered in a daily dose of 20, 30 and 40 mg, respectively, in the same weight categories. The way you can affect tumor cells in the interphase G1-S and S-phase of the cell division cycle, to reduce the population of tumor cells are in the resting phase Go, with a decrease in tumor resistance to radiation and chemotherapy and reduced risk of toxic manifestations.

The invention relates to medicine and can be used mainly in the treatment of neoplastic diseases of the head and neck, biliodigestive zone of the rectum.

Isola (C. L. Taralova and other Original research. Medical radiology, 1986, No. 7, S. 6-13).

The disadvantage of this method is inefficient, since the effects on the primary tumor.

The closest is a method of treatment of cancer patients, including radiation therapy in combination with chemotherapy 5-fluorouracil and platinum source drugs (cisplatin, platinum, sycamore and others) (P. Y. Poles and other non-traditional approaches to radiation treatment of cancer patients. - Oncology, 1997, No. 5, volume 43, S. 487-492).

The disadvantage of this method is that it is not sufficiently effective in tumors with polymorphic structure, significant doses of chemotherapy drugs that cause toxic effects in patients.

The problem posed by the authors, is to eliminate these drawbacks are due to more damaging effects on tumor cells, because they are in the resting phase cells intensively entering a phase of division and chemotherapeutic treatment is more effective, in addition, expanding radiotherapy interval due to the possibility to treat tumors originating from epithelial and Telesystem within 5-7 days with subsequent radiotherapy for 10-12 days in combination with platinum in the first three days of exposure, offered during the three days prior to radiation therapy, and in the first three days concurrently with radiation therapy to prescribe a course of hydroxyacetone at a dose of 500 mg when the weight of the patient of 70 kg, the dose of 1000 mg weight over 70 kg, 1500 mg by weight more than 95 kg orally twice a day with a break at 12 o'clock, while platinochloride drug (second or third class) is administered in a daily dose of 20, 30 and 40 mg, respectively, in the same weight class.

The proposed treatment regimen can influence the tumor, not only in the interphase G1-S, but in the S-phase of the cell division cycle, with suppressed reparation of tumor cells in the treatment process, reduced the population of tumor cells are in the resting phase Go, which implies a reduction of its resistance to radiation therapy and chemotherapy drugs, in addition, affects not only the tumor but also on microinsemination lesions (metastases).

The implementation of the method is demonstrated on specific clinical examples.

Example 1.

Patient M., 62 years old, diagnosis: tumor of the papilla of Vater. Condition after palliative surgical treatment: the imposition of hepaticae, Euro-Euro and gastroenteroanastomosis. Histologically day treatment put a permanent catheter in the right subclavian vein under local anesthesia with 0.5% solution of novocaine, the catheter is fixed with flashing surgical suture. By the method of continuous 96-hour intravenous infusion, 1 to 5 day inclusive with a daily dose of 1000 mg per day entered the total dose of 4.0 g of 5-fluorouracil. In 5, 6, 7, 8, 9, 10 days of treatment with orally twice a day after meals with an interval between receptions in 12 hours the patient received hydroxyurea (hydrea) in a dose of 500 mg to a total dose for the entire period of treatment of 6.0, 8, 9, 10 day of treatment to the patient intravenously by the water load in the breeding of 2.5 liters of solution were injected at 20 mg platydema with the subsequent use of diuretics. After 10 days of intravenous catheter was removed. Remote gamma-therapy was carried out from 8 to 10 a day at a single focal daily dose of 3.6 G to the total focal dose 10,8 G field 88 cm on the device Rocus AM in the mode of sector swing angle 240, and then at a single focal daily dose of 2.4 Grams in 13, 14, 15, 16, 17, 20, 21, 22, 23, 24 days to the total focal daily dose of 34.8 G under the control of platelet and leukocyte in the blood. Then followed a 14-day break in treatment. 38 days in the control ultrasound biliodigestive zones are marked regression of tumor size to 443939 mm 39 SATCOM novocaine, the catheter is fixed surgical suture. By the method of continuous 96-hour intravenous 39 43 day inclusive with a daily dose of 1000 mg per day entered the total dose of 4.0 g of 5-fluorouracil. In 43, 44, 45, 46, 47, 48 days of treatment with orally twice a day after meals with an interval between receptions in 12 hours, the patient took hydrea dose of 500 mg to a total dose for the entire period of treatment 6,0, 46, 47, 48 day of treatment to the patient intravenously by the water load in the breeding of 2.5 liters of solution were injected at 20 mg platydema with the subsequent use of diuretics. At the end of the 48-xdays intravenous catheter was removed. Remote gamma-therapy was carried out with 46 48 day at a single focal daily dose of 3.6 G to the total focal dose 10,8 G field 88 cm on the device Rocus AM in the mode of sector swing angle 240, and then at a single focal daily dose of 2.4 Grams in 51, 52, 53, 54, 55, 58, 59, 60, 61, 62 days to the total focal daily dose of 34.8 G under the control of platelet and leukocyte in the blood. Thus, the total focal dose at two stages amounted to 69.6 Gy.

94 days in the control ultrasound tumor was not determined. The treatment is completed. Thus, predpalazeniea more than a year. In the control ultrasound biliodigestive zone, one year after the start of treatment the tumor is not defined.

According to this method, for 16 months treated 8 patients with the diagnosis of a malignant tumor biliodigestive zone. Condition after palliative surgery overlay “bypass” hepaticae, choledochocele, Euro-Euro-gastroenteroanastomosis. 6 patients are alive and are being monitored in the period from 6 to 13 months. All histomorphologically structure of the tumor is an adenocarcinoma. Of these 4 patients, the tumor regressed completely, with no signs of recurrence. In 2 of the patients have residual tumor to 24 mm in diameter, regression of the tumor more than 80%.

In 2 patients the tumor had histomorphological structure - skirr. 60-65 days from the beginning of treatment in the control ultrasound of the hepatobiliary region revealed multiple liver metastases that were not previously defined. Course radiopolitics was carried out in full. Radiation treatment was completed at a dose of 60 Gy. The life expectancy of these patients from the start of radiation therapy was 4.5 and 6 months, which is higher than the average data 1.3-1.4 times.

Example 2.

Patient, 55 years of age, the diagnosis of tumors. what about the data of the external examination determined the size of the tumor: 3,52,51,8-2.0 cm, the tumor does not pass over the middle line of the tongue.

1 through 5 day treatment including patient were conducted daily 5-hour intravenous drip of 5-fluorouracil 750 mg on the device DOV-1. In 5, 6, 7, 8, 9, 10 days of treatment with orally twice a day after meals with an interval between receptions in 12 hours, the patient took hydrea dose of 1000 mg to a total dose for the entire period of treatment 12,0, 8, 9, 10 day of treatment to the patient intravenously by the water load in the breeding of 2.5 liters of solution was administered 30 mg of cisplatin followed by the application of diuretics. Remote gamma-therapy was carried out from 8 to 10 a day at a single focal daily dose of 3.6 G to the total focal dose to 10.8 G of 2-counter fields 69 cm on the device “agate-R”, and then at a single focal daily dose of 2.4 Grams in 13, 14, 15, 16, 17, 20, 21, 22, 23, 24 days up to a total focal dose to the primary tumor site to 34.8 G under the control of platelet and leukocyte in the blood. In addition, radiation therapy (remote gamma-therapy) was held in 13, 14, 15, 16, 17, 20, 21, 22, 23, 24 days of treatment at area 2 and 3 barriers to regional lymph two (left and right) cervical-Nadel. Then came the 16-day break in treatment. According to the external examination on day 41, the tumor decreased to 2,01,51,5 see page 41 of 64 day care conducted a similar course of radiological three chemotherapeutic drugs and radiation therapy to the primary tumor site. Thus, the total focal dose radiation therapy for 2 stage amounted to 69.6 Gy. Radiation therapy of the cervical lymph nodes at the second stage of treatment had not been carried out. At the control examination for 96 days from the beginning of treatment the tumor was completely subjected to regression.

According to this method, for 9 months treated 20 patients with a diagnosis of oropharyngeal tumor area. All histomorphologically confirmation of diagnosis: squamous cell carcinoma of varying degrees of differentiation. In 9 patients the tumor was completely cured. In 11 patients noted a significant more than 90% regression of tumor, which required a chemotherapy or surgery.

Example 3.

Patient Z., 48 years old, height 158 cm, weight 95 kg, the diagnosis of Tumor of the rectum. Condition after palliative surgery overlay salmostoma, diagnostic biopsy. Histomorphologically: a study of glandular cancer.

The patient with sommaroy doses of 5.0, 5 through day 9, the patient received orally after meals twice a day to 1500 mg of hydroxyacetone interval between receptions in 12 hours. The total dose of the drug was 15,0, From 8 to day 10, the patient received sycamore 40 mg intravenous drip water load in a dilution of 2.5 liters of solution with the subsequent use of diuretics. Remote gamma-therapy was carried out from 8 to 10 a day at a single focal daily dose of 3.6 G to the total focal dose to 10.8 G of 2-counter curly fields 1418 cm on the device “agate-R”, and then at a single focal daily dose of 2.4 Grams in 13, 14, 15, 16, 17, 20, 21, 22, 23, 24 days up to a total focal dose to the primary tumor site to 34.8 G under the control of platelet and leukocyte in the blood. After 18 days the patient had a CT scan study: the tumor has been reduced by more than 80%. The tumor is deemed resectable. The patient had an operation - resection of the rectum with the imposition of the anastomosis side-to-side” with the subsequent liquidation of salmostoma and restoration of the passage of intestinal contents through the intestines and evacuation of feces through the natural anus.

According to this method, treated 2 patients diagnosed with adenocarcinoma of the rectum. In both cases, the treatment is ishaat the risk of toxic effects, improves the quality of life of patients.

The method of treatment of cancer patients, including chemotherapy 5-fluorouracil followed by radiotherapy in combination with platinum source drug in the first three days of irradiation, characterized in that the prescribed course of hydroxyacetone within three days prior to radiation therapy, and in the first two or three days along with radiation therapy 500 mg when the weight of the patient of 70 kg, 1000 mg weight over 70 kg, 1500 mg by weight more than 95 kg orally twice a day with an interval of 12 h, while platinochloride the drug is administered in a daily dose of 20 mg, 30 mg and 40 mg, respectively, in the same weight categories.

 

Same patents:

The invention relates to palletization derived bacteriochlorophyll formula I, I' or I"

where a is a HE, OR1, -O-(CH2)n-Y, -S-(CH2)n-Y, -NH-(CH2)n-Y, -O-(CH2)2-OH, -NH-(CH2)2-NH-BOC, or-N(CH2-CH=CH2)2where R1represents Na+, K+, (CA2+)0,5, (Mg2+)0,5Li+, NH+4,+NH3-C(CH2OH)3,+NH3-CH2-(CHOH)4-CH2OH,+NH2(CH3)-CH2(SNON)4-CH2OH, or+N(Cn'H2n'+1)4; R2represents N or C1-C12the alkyl for the compounds of formula I', and R2represents H, HE or COOR4for the compounds of formula I, where R4represents C1-C12alkyl or C3-C12cycloalkyl; R3represents N or C1-C12the alkyl for the compounds of formula I', and R3represents H, HE, or C1-C12alkyl or alkoxy with the R'3X-where R'1, R'2and R'3each independently represents-CH3or-C2H5; X represents F, Cl, Br or I, n is 1, 2, 3 or 4, and where * denotes an asymmetric carbon atom and --- represents a single saturated bond or an unsaturated double bond pharmaceutical composition having a capacity of detection or treatment of tumors containing at least one compound of formula I, I' or I", three methods for obtaining the compounds of formula I

The invention relates to derived-alanine General formula I:

in which Q1or Q3independently from each other represent CH or N, they cannot mean N; R1represents H, A, Ar or Hal, R2denotes H or A,

each of R4and R5independently denotes H, a or Hal, R6represents H or a, a denotes alkyl with 1-6 carbon atoms, Ar is an unsubstituted aryl, Hal denotes F, Cl, Br or I, n is 2, 3, 4, 5 or 6, m is 1, 2, 3 or 4, as well as their physiologically acceptable salt and solvate; two methods for their preparation and pharmaceutical product having the properties of integrins inhibitor

The invention relates to medicine, to methods of combination therapy for cancer patients

The invention relates to medicine, namely to breast care, gynecology, endocrinology

The invention relates to biology and medicine
The invention relates to medicine, specifically to Oncology, and can be used in clinical practice Oncology hospitals

The invention relates to compounds represented by formulas (I), (II), (III)

The proposed compound of formula M as an intermediate product,

where R denotes the ethyl radical

-oxidase from the fungus of the genus trichoderma and method for producing this enzyme" target="_blank">

The invention relates to medicine, in particular to polyfunctional compounds based derivative of L-lysine--oxidase from the fungus Trichoderma and method for producing this enzyme
The invention relates to medicine and is intended for the treatment of erectile dysfunction
The invention relates to the field of veterinary medicine
The invention relates to medicine, in particular therapy, and can be used in medical institutions for the treatment of pain in patients with chronic somatic diseases
The invention relates to the pharmaceutical field, in particular to treatments for trauma, and can be used to ensure thermal, solar, chemical, and infected burns of various degrees, of wounds of different origin and frostbite
The invention relates to medicine, namely to otolaryngology, and can be used for the treatment of patients with neoplasms of male genital organs

The invention relates to medicine, namely to the dentist, and for the prevention of caries
The invention relates to medicine, ophthalmology, may be used for the treatment of uveitis
The invention relates to medicine, namely to ophthalmology, and can be used for treatment of degenerative diseases of the cornea
The invention relates to ophthalmology, and can be used for the treatment of recurrent case after Subtotal vitrectomy and in treatment of swelling and hemorrhagic forms of diabetic retinopathy or in those cases when you need a short-term tamponade performancesin connection (PFOS) of the vitreous cavity
The invention relates to ophthalmology

The invention relates to derived-alanine General formula I:

in which Q1or Q3independently from each other represent CH or N, they cannot mean N; R1represents H, A, Ar or Hal, R2denotes H or A,

each of R4and R5independently denotes H, a or Hal, R6represents H or a, a denotes alkyl with 1-6 carbon atoms, Ar is an unsubstituted aryl, Hal denotes F, Cl, Br or I, n is 2, 3, 4, 5 or 6, m is 1, 2, 3 or 4, as well as their physiologically acceptable salt and solvate; two methods for their preparation and pharmaceutical product having the properties of integrins inhibitor
Up!